BioCryst Pharmaceuticals BCRX Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from BioCryst Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's asset turnover?
- BioCryst Pharmaceuticals (BCRX) reported asset turnover of 1.9× in Q1 2026.
- How has BioCryst Pharmaceuticals's asset turnover changed year-over-year?
- BioCryst Pharmaceuticals's asset turnover increased by 76.4% year-over-year, from 1.1× to 1.9×.
- What is the long-term trend for BioCryst Pharmaceuticals's asset turnover?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's asset turnover has grown at a 90.2% compound annual growth rate (CAGR), from 0.1× to 1.7×.
- What does asset turnover mean?
- Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.